日本語
.jpg)
2018
Shanghai, China, December 8, 2018--Shanghai HaiHe Biopharma Co., Ltd. (hereinafter referred to as “HaiHe Biopharma”). The national investigator meeting on the pivotal phase IIb clinical trial of Lucitanib AL3810-202 , an innovative drug of Category I developed by HaiHe Biopharma, for treatment of thymic cancer was successfully convened in Guangzhou recently. The Chief Physician Prof. Fang Wentao of the Dept. of Thoracic Surgery of Shanghai Chest Hospital acts as the PI and Prof. Zhou Caicun of the Dept. of Internal Medicine-Oncology of Shanghai Pulmonary Hospital acts as the co-PI of the clinical trial.
“The investigators and experts from 17 sites nationwide gathered together in Guangzhou to attend the national investigator meeting convened by HaiHe Biopharma on the pivotal phase IIb clinical trial of Lucitanib AL3810-202 for discussions on the application of Lucitanib for treatment of advanced relapse or metastatic thymic cancer with first-line chemotherapy failure . The successful convening of the investigator meeting accelerated the advancement of the clinical trial. We will work dedicatedly together with the experts from multiple centers across the country to bring Lucitanib to market and benefit the Chinese cancer patients as early as possible,” said Dr. Dong Ruiping, CEO of HaiHe Biopharma.
“Very happy to see the successful convening of the national investigator meeting on the pivotal phase IIb clinical trial of AL3810-202 for treatment of thymic cancer. The AL3810-202 trial is aimed at addressing the unmet clinical needs for advanced relapse or metastatic thymic cancer with first-line chemotherapy failure. We are very optimistic about the clinical application prospects of the drug and it is our common responsibility to promote the launch of the safe and effective innovative drugs. We will work hard together with a number of the research centers nationwide to expedite the launch of the drug so as to benefit even more cancer patients in China,” said Professor Fang Wentyao, Chief Physician of the Department of Thoracic Surgery of Shanghai Chest Hospital.
Lucitanib (Code: AL3810) is a three-target oral small molecule kinase inhibitor targeting FGFR1–3, VEGFR1–3 and PDGFRα/β, which is jointly studied by Shanghai Institute of Materia Medica, Chinese Academy of Sciences and its partners. HaiHe Biopharma is responsible for the clinical development, production and commercialization of the drug in China. Preclinical studies have shown that the compound Lucitanib has a strong antitumor activity in vitro and in various animal tumor models. Clinical studies conducted in Europe have shown itsefficacy on alignant tumors including breast cancer and NSCLC etc. with manageable safety.
Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions.
